These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28850362)

  • 1. Quantitative sensory tests fairly reflect immediate effects of oxycodone in chronic low-back pain.
    Schliessbach J; Siegenthaler A; Bütikofer L; Vuilleumier P; Jüni P; Arendt-Nielsen L; Curatolo M
    Scand J Pain; 2017 Oct; 17():107-115. PubMed ID: 28850362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting drug efficacy in chronic low back pain by quantitative sensory tests.
    Schliessbach J; Siegenthaler A; Bütikofer L; Vuilleumier P; Jüni P; Stamer U; Arendt-Nielsen L; Curatolo M
    Eur J Pain; 2018 May; 22(5):973-988. PubMed ID: 29363217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain.
    Siegenthaler A; Schliessbach J; Vuilleumier PH; Juni P; Zeilhofer HU; Arendt-Nielsen L; Curatolo M
    BMC Pharmacol Toxicol; 2015 Sep; 16():23. PubMed ID: 26376691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
    Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
    Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of single-dose imipramine on chronic low-back and experimental pain. A randomized controlled trial.
    Schliessbach J; Siegenthaler A; Bütikofer L; Limacher A; Juni P; Vuilleumier PH; Stamer U; Arendt-Nielsen L; Curatolo M
    PLoS One; 2018; 13(5):e0195776. PubMed ID: 29742109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects.
    Eisenberg E; Midbari A; Haddad M; Pud D
    Pain; 2010 Oct; 151(1):104-109. PubMed ID: 20621419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study.
    Singla N; Pong A; Newman K;
    Clin Ther; 2005 Jan; 27(1):45-57. PubMed ID: 15763605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative sensory tests (QST) are promising tests for clinical relevance of anti-nociceptive effects of new analgesic treatments.
    Jääskeläinen SK
    Scand J Pain; 2017 Oct; 17():144-145. PubMed ID: 28865379
    [No Abstract]   [Full Text] [Related]  

  • 12. Does long-term opioid therapy reduce pain sensitivity of patients with chronic low back pain? Evidence from quantitative sensory testing.
    Wang H; Fischer C; Chen G; Weinsheimer N; Gantz S; Schiltenwolf M
    Pain Physician; 2012 Jul; 15(3 Suppl):ES135-43. PubMed ID: 22786452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: a crossover, randomised, double-blinded, placebo-controlled study.
    Wetzel L; Zadrazil M; Paternostro-Sluga T; Authried G; Kozek-Langenecker S; Scharbert G
    Eur J Anaesthesiol; 2014 Jan; 31(1):35-40. PubMed ID: 24141646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model.
    Litkowski LJ; Christensen SE; Adamson DN; Van Dyke T; Han SH; Newman KB
    Clin Ther; 2005 Apr; 27(4):418-29. PubMed ID: 15922815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.
    Caldwell JR; Hale ME; Boyd RE; Hague JM; Iwan T; Shi M; Lacouture PG
    J Rheumatol; 1999 Apr; 26(4):862-9. PubMed ID: 10229408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol.
    Lin CW; McLachlan AJ; Latimer J; Day RO; Billot L; Koes BW; Maher CG
    BMJ Open; 2016 Aug; 6(8):e011278. PubMed ID: 27558901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Pain Sensitivity and Pain Modulation During Oral Opioid Treatment: The Impact of Negative Affect.
    Edwards RR; Dolman AJ; Michna E; Katz JN; Nedeljkovic SS; Janfaza D; Isaac Z; Martel MO; Jamison RN; Wasan AD
    Pain Med; 2016 Oct; 17(10):1882-1891. PubMed ID: 26933094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial and novel mathematical analysis of the analgesic effect of oxycodone versus paracetamol orodispersible tablets.
    Martini CH; Proto P; Olofsen E; van Velzen M; Aarts L; Dahan A; Niesters M
    Eur J Pain; 2015 Mar; 19(3):295-304. PubMed ID: 24947675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study.
    Olesen AE; Staahl C; Arendt-Nielsen L; Drewes AM
    Br J Clin Pharmacol; 2010 Aug; 70(2):189-200. PubMed ID: 20653672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.